{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,15]],"date-time":"2026-04-15T05:49:48Z","timestamp":1776232188444,"version":"3.50.1"},"reference-count":47,"publisher":"Oxford University Press (OUP)","issue":"3","license":[{"start":{"date-parts":[[2025,11,10]],"date-time":"2025-11-10T00:00:00Z","timestamp":1762732800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"name":"Boehringer Ingelheim Co., Ltd."}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,4,13]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Objectives<\/jats:title>\n                    <jats:p>We established a multicentre prospective registry of patients with systemic sclerosis (SSc) in Japan to evaluate the outcomes in the modern treatment era. This report presents the baseline characteristics of patients enrolled in the registry.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Adult SSc patients were prospectively enrolled from 20 medical centres across Japan. Baseline data, including demographics, organ involvement, autoantibody profiles, and patient-reported outcomes, were collected using a dedicated electronic data capture system.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>A total of 835 patients were eligible for analysis. The cohort was predominantly female (85.1%), with a median age of 64\u00a0years at enrolment, and 35.0% had diffuse cutaneous SSc. Autoantibodies included anticentromere (38.9%), anti-topoisomerase I (topo I; 33.5%), anti-RNA polymerase III (RNAP III; 12.4%), and anti-U1 RNP (12.9%). Interstitial lung disease (ILD) was the most common organ manifestation (56.0%), followed by upper gastrointestinal (GI) involvement (42.5%), heart involvement (5.3%), pulmonary hypertension (3.4%), scleroderma renal crisis (1.9%), and lower GI involvement (1.2%). Patients with anti-topo I had the worst patient global assessment, whereas those with anti-RNAP III patients had the worst physician global assessment.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>This prospective registry captures real-world data on SSc patients, providing a valuable resource for understanding the clinical spectrum and outcomes in contemporary practice in Japan.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/mr\/roaf109","type":"journal-article","created":{"date-parts":[[2025,11,6]],"date-time":"2025-11-06T13:20:19Z","timestamp":1762435219000},"page":"396-406","source":"Crossref","is-referenced-by-count":0,"title":["A multicentre, prospective registry of patients with systemic sclerosis in Japan: baseline patient characteristics"],"prefix":"10.1093","volume":"36","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8352-6136","authenticated-orcid":false,"given":"Masataka","family":"Kuwana","sequence":"first","affiliation":[{"name":"Department of Allergy and Rheumatology, Nippon Medical School , Tokyo ,","place":["Japan"]},{"name":"Scleroderma\/Myositis Center of Excellence, Nippon Medical School Hospital , Tokyo ,","place":["Japan"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shinji","family":"Watanabe","sequence":"additional","affiliation":[{"name":"Department of Allergy and Rheumatology, Nippon Medical School , Tokyo ,","place":["Japan"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tohru","family":"Takeuchi","sequence":"additional","affiliation":[{"name":"Division of Rheumatology, Department of Internal Medicine (IV), Osaka Medical and Pharmaceutical University , Osaka ,","place":["Japan"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuko","family":"Kaneko","sequence":"additional","affiliation":[{"name":"Division of Rheumatology, Department of Internal Medicine, Keio University School of Medicine , Tokyo ,","place":["Japan"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yasushi","family":"Kawaguchi","sequence":"additional","affiliation":[{"name":"Division of Rheumatology, Department of Internal Medicine, Tokyo Women's Medical University , Tokyo ,","place":["Japan"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yoshiya","family":"Tanaka","sequence":"additional","affiliation":[{"name":"Department of Molecular Targeted Therapeutics, School of Medicine , University of Occupational and Environmental Health, Japan, Kitakyushu ,","place":["Japan"]},{"name":"The First Department of Internal Medicine, University of Occupational and Environmental, Health, Japan , Kitakyushu ,","place":["Japan"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yukie","family":"Yamaguchi","sequence":"additional","affiliation":[{"name":"Department of Environmental Immuno-Dermatology, Yokohama City University Graduate School of Medicine , Yokohama ,","place":["Japan"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hiroaki","family":"Dobashi","sequence":"additional","affiliation":[{"name":"Division of Hematology, Rheumatology and Respiratory Medicine, Department of Internal Medicine, Faculty of Medicine, Kagawa University , Takamatsu ,","place":["Japan"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yusho","family":"Ishii","sequence":"additional","affiliation":[{"name":"Department of Rheumatology, Tohoku University Hospital , Sendai ,","place":["Japan"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hiroaki","family":"Niiro","sequence":"additional","affiliation":[{"name":"Department of Medical Education, Kyushu University Graduate School of Medical Sciences , Fukuoka ,","place":["Japan"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Masanari","family":"Kodera","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Japan Community Health Care Organisation Chukyo Hospital , Nagoya ,","place":["Japan"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hidekata","family":"Yasuoka","sequence":"additional","affiliation":[{"name":"Division of Rheumatology, Department of Internal Medicine, Fujita Health University School of Medicine , Toyoake ,","place":["Japan"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tatsuya","family":"Atsumi","sequence":"additional","affiliation":[{"name":"Department of Rheumatology, Endocrinology and Nephrology, Faculty of Medicine and Graduate School of Medicine, Hokkaido University , Sapporo ,","place":["Japan"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hiroki","family":"Takahashi","sequence":"additional","affiliation":[{"name":"Division of Rheumatology and Clinical Immunology, Department of Internal Medicine, Sapporo Medical University School of Medicine , Sapporo ,","place":["Japan"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Naoki","family":"Iwamoto","sequence":"additional","affiliation":[{"name":"Department of Immunology and Rheumatology, Division of Advanced Preventive Medical Sciences, Nagasaki University Graduate School of Medical Sciences , Nagasaki ,","place":["Japan"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yu","family":"Matsueda","sequence":"additional","affiliation":[{"name":"Department of Rheumatology, Kitasato University School of Medicine , Sagamihara ,","place":["Japan"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yohei","family":"Isomura","sequence":"additional","affiliation":[{"name":"Department of Allergy and Rheumatology, Nippon Medical School , Tokyo ,","place":["Japan"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yasuhiro","family":"Kondoh","sequence":"additional","affiliation":[{"name":"Department of Respiratory Medicine and Allergology, Tosei General Hospital , Seto ,","place":["Japan"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuichi","family":"Tamura","sequence":"additional","affiliation":[{"name":"Pulmonary Hypertension Center, International University of Health and Welfare Mita Hospital , Tokyo ,","place":["Japan"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"name":"J-STAR investigators","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2025,11,10]]},"reference":[{"key":"2026041500570230900_ref1","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1007\/s12016-021-08891-0","article-title":"Therapeutic approaches to systemic sclerosis: recent approvals and future candidate therapies","volume":"64","author":"Lescoat","year":"2023","journal-title":"Clin Rev Allergy Immunol"},{"key":"2026041500570230900_ref2","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1136\/ard-2024-226430","article-title":"EULAR recommendations for the treatment of systemic sclerosis: 2023 update","volume":"84","author":"Del Galdo","year":"2025","journal-title":"Ann Rheum Dis"},{"key":"2026041500570230900_ref3","first-page":"1067","article-title":"Canadian scleroderma research group; Australian scleroderma interest group. Early mortality in a multinational systemic sclerosis inception cohort. Arthritis","volume":"69","author":"Hao","year":"2017","journal-title":"Rheumatol."},{"key":"2026041500570230900_ref4","doi-asserted-by":"crossref","first-page":"1809","DOI":"10.1136\/ard.2009.114264","article-title":"Causes and risk factor for death in systemic sclerosis: a study from the EULAR scleroderma trials and research (EUSTAR) database","volume":"69","author":"Tyndall","year":"2010","journal-title":"Ann Rheum Dis"},{"key":"2026041500570230900_ref5","doi-asserted-by":"crossref","first-page":"2222","DOI":"10.1007\/s12325-022-02078-5","article-title":"Incidence rate and prevalence of systemic sclerosis and systemic sclerosis-associated interstitial lung disease in Japan: analysis using Japanese claims databases","volume":"39","author":"Kuwana","year":"2022","journal-title":"Adv Ther"},{"key":"2026041500570230900_ref6","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1056\/NEJMra1614394","article-title":"Evidence for health decision making \u2013 beyond randomized, controlled trials","volume":"377","author":"Frieden","year":"2017","journal-title":"New Engl J Med"},{"key":"2026041500570230900_ref7","doi-asserted-by":"crossref","first-page":"1107","DOI":"10.1136\/ard.2005.036038","article-title":"Systemic sclerosis in Europe: first report from the EULAR scleroderma trials and research (EUSTAR) group database","volume":"64","author":"Tyndall","year":"2005","journal-title":"Ann Rheum Dis"},{"key":"2026041500570230900_ref8","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1186\/s13075-024-03418-2","article-title":"Does regression of skin thickening predict improvement of internal organ involvement and survival in patients with diffuse cutaneous systemic sclerosis?","volume":"26","author":"Wyss","year":"2024","journal-title":"A EUSTAR analysis Arthritis Res Ther"},{"key":"2026041500570230900_ref9","doi-asserted-by":"crossref","first-page":"1185","DOI":"10.1093\/rheumatology\/ken179","article-title":"The registry of the German network for systemic scleroderma: frequency of disease subsets and patterns of organ involvement","volume":"47","author":"Hunzelmann","year":"2008","journal-title":"Rheumatology (Oxford)"},{"key":"2026041500570230900_ref10","doi-asserted-by":"crossref","first-page":"2737","DOI":"10.3899\/jrheum.090694","article-title":"Malnutrition is common in systemic sclerosis: results from the Canadian scleroderma research group database","volume":"36","author":"Baron","year":"2009","journal-title":"J Rheumatol"},{"key":"2026041500570230900_ref11","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1164\/rccm.202306-1113ST","article-title":"Treatment of systemic sclerosis-associated interstitial lung disease: evidence-based recommendations. An official American Thoracic Society clinical practice guideline","volume":"209","author":"Raghu","year":"2024","journal-title":"Am J Respir Crit Care Med"},{"key":"2026041500570230900_ref12","doi-asserted-by":"crossref","first-page":"1201","DOI":"10.1002\/art.42860","article-title":"2023 American College of Rheumatology (ACR)\/American college of CHEST physicians (CHEST) guideline for the screening and monitoring of interstitial lung disease in people with systemic autoimmune rheumatic diseases","volume":"76","author":"Johnson","year":"2024","journal-title":"Arthritis Rheumatol."},{"key":"2026041500570230900_ref13","doi-asserted-by":"crossref","first-page":"1051","DOI":"10.1002\/acr.25348","article-title":"2023 American College of Rheumatology (ACR)\/American college of CHEST physicians (CHEST) guideline for the treatment of interstitial lung disease in people with systemic autoimmune rheumatic diseases","volume":"76","author":"Johnson","year":"2024","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"2026041500570230900_ref14","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1002\/1529-0131(199904)42:3<465::AID-ANR11>3.0.CO;2-Y","article-title":"Influence of ethnic background on clinical and serologic features in patients with systemic sclerosis and anti-DNA topoisomerase I antibody","volume":"42","author":"Kuwana","year":"1999","journal-title":"Arthritis Rheum"},{"key":"2026041500570230900_ref15","doi-asserted-by":"crossref","first-page":"1747","DOI":"10.1136\/annrheumdis-2013-204424","article-title":"2013 classification criteria for systemic sclerosis: an American College of Rheumatology\/European league against rheumatism collaborative initiative","volume":"72","author":"Hoogen","year":"2013","journal-title":"Ann Rheum Dis"},{"key":"2026041500570230900_ref16","doi-asserted-by":"crossref","first-page":"11","DOI":"10.5301\/jsrd.5000231","article-title":"Standardization of the modified Rodnan skin score for use in clinical trials of systemic sclerosis","volume":"2","author":"Khanna","year":"2017","journal-title":"J Scleroderma Relat Disord."},{"key":"2026041500570230900_ref17","doi-asserted-by":"crossref","first-page":"102458","DOI":"10.1016\/j.autrev.2020.102458","article-title":"EULAR study group on microcirculation in rheumatic diseases and the scleroderma clinical trials consortium group on capillaroscopy. Standardisation of nailfold capillaroscopy for the assessment of patients with Raynaud's phenomenon and systemic sclerosis","volume":"19","author":"Smith","year":"2020","journal-title":"Autoimmun Rev"},{"key":"2026041500570230900_ref18","doi-asserted-by":"crossref","first-page":"1248","DOI":"10.1164\/rccm.200706-877OC","article-title":"Interstitial lung disease in systemic sclerosis. A simple staging system","volume":"177","author":"Goh","year":"2008","journal-title":"Am J Respir Crit Care Med"},{"key":"2026041500570230900_ref19","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1378\/chest.07-2444","article-title":"Scleroderma lung study research group. High-resolution CT scan findings in patients with symptomatic scleroderma-related interstitial lung disease","volume":"134","author":"Goldin","year":"2008","journal-title":"Chest"},{"key":"2026041500570230900_ref20","doi-asserted-by":"crossref","first-page":"1984","DOI":"10.1002\/art.1780401110","article-title":"The value of the health assessment questionnaire and special patient-generated scales to demonstrate change in systemic sclerosis patients over time","volume":"40","author":"Steen","year":"1997","journal-title":"Arthritis Rheum"},{"key":"2026041500570230900_ref21","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1177\/23971983231181719","article-title":"The long-term course of the health assessment questionnaire in patients with systemic sclerosis","volume":"8","author":"Ie Liem","year":"2023","journal-title":"J Scleroderma Relat Disord."},{"key":"2026041500570230900_ref22","doi-asserted-by":"crossref","first-page":"1374","DOI":"10.1136\/annrheumdis-2016-210534","article-title":"Development and validation of a patient-reported outcome instrument for skin involvement in patients with systemic sclerosis","volume":"76","author":"Man","year":"2017","journal-title":"Ann Rheum Dis"},{"key":"2026041500570230900_ref23","doi-asserted-by":"crossref","first-page":"1257","DOI":"10.1002\/art.24730","article-title":"Reliability and validity of the University of California, los Angeles scleroderma clinical trial consortium gastrointestinal tract instrument","volume":"61","author":"Khanna","year":"2009","journal-title":"Arthritis Rheum"},{"key":"2026041500570230900_ref24","doi-asserted-by":"crossref","first-page":"932","DOI":"10.1183\/09031936.04.00014304","article-title":"Standards for the diagnosis and treatment of patients with COPD: a summary of the ATS\/ERS position paper","volume":"23","author":"Celli","year":"2004","journal-title":"Eur Respir J"},{"key":"2026041500570230900_ref25","doi-asserted-by":"crossref","first-page":"804","DOI":"10.1136\/thoraxjnl-2012-201581","article-title":"The development and validation of the King's brief interstitial lung disease (K-BILD) health status questionnaire","volume":"67","author":"Patel","year":"2012","journal-title":"Thorax."},{"key":"2026041500570230900_ref26","doi-asserted-by":"crossref","first-page":"1443","DOI":"10.1002\/acr.25056","article-title":"Patient and physician global assessments of disease status in systemic sclerosis","volume":"75","author":"Ross","year":"2023","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"2026041500570230900_ref27","doi-asserted-by":"crossref","first-page":"e0163894","DOI":"10.1371\/journal.pone.0163894","article-title":"Incidences and risk factors of organ manifestations in the early course of systemic sclerosis: a longitudinal EUSTAR study","volume":"11","author":"Jaeger","year":"2016","journal-title":"PLoS One"},{"key":"2026041500570230900_ref28","doi-asserted-by":"crossref","first-page":"1355","DOI":"10.1136\/annrheumdis-2011-200742","article-title":"Update on the profile of the EUSTAR cohort: an analysis of the EULAR scleroderma trials and research group database","volume":"71","author":"Meier","year":"2012","journal-title":"Ann Rheum Dis"},{"key":"2026041500570230900_ref29","doi-asserted-by":"crossref","first-page":"1825","DOI":"10.3899\/jrheum.160339","article-title":"Elevated serum Krebs von den Lungen-6 in early disease predicts subsequent deterioration of pulmonary function in patients with systemic sclerosis and interstitial lung disease","volume":"43","author":"Kuwana","year":"2016","journal-title":"J Rheumatol"},{"key":"2026041500570230900_ref30","doi-asserted-by":"crossref","first-page":"1801913","DOI":"10.1183\/13993003.01913-2018","article-title":"Haemodynamic definitions and updated clinical classification of pulmonary hypertension","volume":"53","author":"Simonneau","year":"2019","journal-title":"Eur Respir J"},{"key":"2026041500570230900_ref31","doi-asserted-by":"crossref","first-page":"964","DOI":"10.1002\/art.40809","article-title":"Generation of a core set of items to develop classification criteria for scleroderma renal crisis using consensus methodology","volume":"71","author":"Butler","year":"2019","journal-title":"Arthritis Rheumatol"},{"key":"2026041500570230900_ref32","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1177\/23971983211053246","article-title":"Primary systemic sclerosis heart involvement: a systematic literature review and preliminary data-driven, consensus-based WSF\/HFA definition","volume":"7","author":"Bruni","year":"2022","journal-title":"J Scleroderma Relat Disord"},{"key":"2026041500570230900_ref33","doi-asserted-by":"crossref","first-page":"115","DOI":"10.5301\/jsrd.5000236","article-title":"Defining skin ulcers in systemic sclerosis: systematic literature review and proposed world Scleroderma Foundation (WSF) definition","volume":"2","author":"Suliman","year":"2017","journal-title":"J Scleroderma Relat Disord."},{"key":"2026041500570230900_ref34","doi-asserted-by":"crossref","first-page":"272","DOI":"10.3109\/s10165-011-0515-7","article-title":"Clinical features of 405 Japanese patients with systemic sclerosis","volume":"22","author":"Hashimoto","year":"2012","journal-title":"Mod Rheumatol"},{"key":"2026041500570230900_ref35","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1002\/acr.22163","article-title":"Autoantibodies to RuvBL1 and RuvBL2: a novel systemic sclerosis-related antibody associated with diffuse cutaneous and skeletal muscle involvement","volume":"66","author":"Kaji","year":"2014","journal-title":"Arthritis Care Res (Hoboken)."},{"key":"2026041500570230900_ref36","doi-asserted-by":"crossref","first-page":"803","DOI":"10.1111\/1756-185X.14121","article-title":"Characteristics of Japanese patients with systemic sclerosis complicated with calcinosis","volume":"24","author":"Takagi","year":"2021","journal-title":"Int J Rheum Dis"},{"key":"2026041500570230900_ref37","doi-asserted-by":"crossref","first-page":"e004101","DOI":"10.1136\/rmdopen-2024-004101","article-title":"Untangling the relationship between smoking and systemic sclerosis: an analysis of the EUSTAR cohort","volume":"10","author":"Ciaffi","year":"2024","journal-title":"RMD Open"},{"key":"2026041500570230900_ref38","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1272\/jnms.84.56","article-title":"Circulating anti-nuclear antibodies in systemic sclerosis: utility in diagnosis and disease subsetting","volume":"84","author":"Kuwana","year":"2017","journal-title":"J Nippon Med Sch"},{"key":"2026041500570230900_ref39","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1002\/art.41153","article-title":"Using autoantibodies and cutaneous subset to develop outcome-based disease classification in systemic sclerosis","volume":"72","author":"Nihtyanova","year":"2020","journal-title":"Arthritis Rheumatol"},{"key":"2026041500570230900_ref40","doi-asserted-by":"crossref","first-page":"11212","DOI":"10.1038\/s41598-022-15062-4","article-title":"Combinations of scleroderma hallmark autoantibodies associate with distinct clinical phenotypes","volume":"12","author":"Clark","year":"2022","journal-title":"Sci Rep"},{"key":"2026041500570230900_ref41","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1002\/art.1780370111","article-title":"Clinical and prognostic associations based on serum antinuclear antibodies in Japanese patients with systemic sclerosis","volume":"37","author":"Kuwana","year":"1994","journal-title":"Arthritis Rheum"},{"key":"2026041500570230900_ref42","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1177\/2397198319886496","article-title":"Patient-reported outcome instruments in clinical trials of systemic sclerosis","volume":"5","author":"Pauling","year":"2020","journal-title":"J Scleroderma Relat Disord"},{"key":"2026041500570230900_ref43","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1586\/14737167.2013.814957","article-title":"US FDA patient-reported outcome guidance: great expectations and unintended consequences","volume":"13","author":"Fehnel","year":"2013","journal-title":"Expert Rev Pharmacoecon Outcomes Res"},{"key":"2026041500570230900_ref44","doi-asserted-by":"crossref","first-page":"925","DOI":"10.1007\/s40258-023-00827-3","article-title":"The assessment of patient-reported outcomes for the authorisation of medicines in Europe: a review of European public assessment reports from 2017 to 2022","volume":"21","author":"Meregaglia","year":"2023","journal-title":"Appl Health Econ Health Policy"},{"key":"2026041500570230900_ref45","doi-asserted-by":"crossref","first-page":"353","DOI":"10.2147\/PROM.S156279","article-title":"The importance of patient-reported outcomes in clinical trials and strategies for future optimization","volume":"Volume 9","author":"Mercieca-Bebber","year":"2018","journal-title":"Patient Relat Outcome Meas"},{"key":"2026041500570230900_ref46","doi-asserted-by":"crossref","first-page":"2307","DOI":"10.3899\/jrheum.100354","article-title":"Canadian scleroderma research group; Steele R. Discordance between patient and physician assessments of disease severity in systemic sclerosis","volume":"37","author":"Hudson","year":"2010","journal-title":"J Rheumatol"},{"key":"2026041500570230900_ref47","doi-asserted-by":"crossref","first-page":"960","DOI":"10.1080\/14397595.2017.1422304","article-title":"Determinants of Patient's global assessment of disease activity and Physician's global assessment of disease activity in patients with rheumatoid arthritis: a post hoc analysis of overall and Japanese results from phase 3 clinical trials","volume":"28","author":"Kaneko","year":"2018","journal-title":"Mod Rheumatol"}],"container-title":["Modern Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/mr\/advance-article-pdf\/doi\/10.1093\/mr\/roaf109\/65253098\/roaf109.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/mr\/article-pdf\/36\/3\/396\/65253098\/roaf109.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/mr\/article-pdf\/36\/3\/396\/65253098\/roaf109.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,15]],"date-time":"2026-04-15T04:57:15Z","timestamp":1776229035000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/mr\/article\/36\/3\/396\/8317960"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,10]]},"references-count":47,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2025,11,10]]},"published-print":{"date-parts":[[2026,4,13]]}},"URL":"https:\/\/doi.org\/10.1093\/mr\/roaf109","relation":{},"ISSN":["1439-7595","1439-7609"],"issn-type":[{"value":"1439-7595","type":"print"},{"value":"1439-7609","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026,5]]},"published":{"date-parts":[[2025,11,10]]}}}